Review



total jnk1 2  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc total jnk1 2
    Total Jnk1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 6861 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total jnk1 2/product/Cell Signaling Technology Inc
    Average 99 stars, based on 6861 article reviews
    total jnk1 2 - by Bioz Stars, 2026-02
    99/100 stars

    Images



    Similar Products

    total-jnk1/2/3  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology total-jnk1/2/3
    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
    Total Jnk1/2/3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total-jnk1/2/3/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    total-jnk1/2/3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    total jnk1 2  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology total jnk1 2
    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
    Total Jnk1 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total jnk1 2/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    total jnk1 2 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    total jnk1/2/3 (1:1000)  (ZenBio)
    90
    ZenBio total jnk1/2/3 (1:1000)
    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
    Total Jnk1/2/3 (1:1000), supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total jnk1/2/3 (1:1000)/product/ZenBio
    Average 90 stars, based on 1 article reviews
    total jnk1/2/3 (1:1000) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    total jnk1/2/3 antibody  (ZenBio)
    90
    ZenBio total jnk1/2/3 antibody
    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
    Total Jnk1/2/3 Antibody, supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total jnk1/2/3 antibody/product/ZenBio
    Average 90 stars, based on 1 article reviews
    total jnk1/2/3 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    total jnk1 2  (Cell Signaling Technology Inc)
    99
    Cell Signaling Technology Inc total jnk1 2
    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
    Total Jnk1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total jnk1 2/product/Cell Signaling Technology Inc
    Average 99 stars, based on 1 article reviews
    total jnk1 2 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    total c-jun n-terminal kinase 1/2 (jnk1/2  (Millipore)
    90
    Millipore total c-jun n-terminal kinase 1/2 (jnk1/2
    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
    Total C Jun N Terminal Kinase 1/2 (Jnk1/2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total c-jun n-terminal kinase 1/2 (jnk1/2/product/Millipore
    Average 90 stars, based on 1 article reviews
    total c-jun n-terminal kinase 1/2 (jnk1/2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated JNK1/2/3 and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.

    Journal: bioRxiv

    Article Title: Glioma-associated fibroblasts promote glioblastoma resistance to temozolomide through CCL2-CCR2 paracrine signaling

    doi: 10.1101/2024.03.05.581575

    Figure Lengend Snippet: (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated JNK1/2/3 and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.

    Article Snippet: Information of primary antibodies was as follows: Fibronectin (BD Biosciences #610077), α-SMA (Proteintech #55135-1-AP), Cleaved-caspase3 (Cell Signaling Technology #9661), Cleaved-caspase9 (Cell Signaling Technology #9509), Bax (Millipore #ABC11), β-Tublin (Millipore #MAB3408), β-Actin (Cell Signaling Technology #3700), GAPDH (Proteintech #CL594-60004), Phospho-ERK1/2(Thr202/Tyr204) (Cell Signaling Technology #4370S), total-ERK1/2 (Cell Signaling Technology #4696), Phospho-p38 MAPK (T180/Y182) (Abclonal #AP1165), total-p38 MAPK (Abcam #ab308333), Phospho-JNK1-T183/Y185+JNK2-T183/Y185+JNK3-T221/Y223 (Abclonal #AP0276), total-JNK1/2/3 (Abclonal #A4867), CCL2/MCP1 (Abclonal # A23288).

    Techniques: Cell Culture, Flow Cytometry, Two Tailed Test